SEC Tracker
Get the app
XENE · XBRL financial data

Xenon Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (XENE's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development4341*44505759*61757788*8999
General and administrative1313*15191718*19191922*2424
Total operating expenses5654*59697477*809496110*112123
Operating income (loss)(56)(54)*(59)(69)(74)(77)*(73)(94)(96)(110)*(112)(123)
Interest income79*1111109*8765*712
Income tax expense (benefit)(0)(0)*0(0)(0)(4)*0(1)11*(3)(1)
Net income (loss)(48)(45)*(48)(58)(63)(66)*(65)(85)(91)(105)*(102)(111)
Earnings per share, basic USD per share(0.73)(0.64)*(0.62)(0.75)(0.81)(0.84)*(0.83)(1.07)(1.15)(1.31)*(1.17)(1.11)
Earnings per share, diluted USD per share(0.73)(0.64)*(0.62)(0.75)(0.81)(0.84)*(0.83)(1.07)(1.15)(1.31)*(1.17)(1.11)
Weighted average shares, basic millions of shares6670*78787878*79797980*87100
Weighted average shares, diluted millions of shares6670*78787878*79797980*87100

Balance sheet

CSV

Fiscal quarters (XENE's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents1001495913788143117135105199546120
Marketable securities427489641585566484433352358350549811
Marketable securities, non-current1122931861291491271411379337245314
Accounts receivable111111——————
Prepaid and other current assets46765771217101114
Total current assets5316457077286606355665004805611,107946
Property and equipment, net101091010101099988
Right-of-use asset999988877765
Total assets6719659198848367987436746086331,3871,296
Accrued liabilities—————————363341
Total current liabilities252722313036323338424045
Lease liability, non-current10109988777665
Total liabilities353731403843394048514953
Accumulated deficit(620)(665)(713)(771)(834)(899)(965)(1,049)(1,140)(1,245)(1,348)(1,458)
Total stockholders' equity6379288888447987557046345605821,3381,242
Total liabilities and equity6719659198848367987436746086331,3871,296
Common shares outstanding (cover page) millions of shares657575767677777777839797

Cash flows

CSV

Fiscal quarters (XENE's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(48)(45)*(48)(58)(63)(66)*(65)(85)(91)(105)*(102)(111)
Stock-based compensation9*9*9151314*12141414*1717
Net cash from operating activities(42)*(35)*(43)(33)*(51)*(54)*(62)(64)*(72)*(81)*(89)(95)*
Purchases of property and equipment1*0*02*1*1*00*0*0*00*
Net cash from investing activities48*(240)*(46)111*2*99*3582*39*63*(407)(331)*
Net cash from financing activities—324*00*0*12*10*2*114*8430*
Net change in cash35*49*(90)78*(49)*55*(26)19*(31)*95*347(426)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Xenon Pharmaceuticals120not reported(95)*96.8M9.8 quarters 10-QJun 30, 2026
Summit Therapeutics419not reported(141)*797.7M4.9 quarters 10-QJun 30, 2026
Twist Bioscience117not reported1.1*62.7M— 10-QJun 30, 2026
Cytokinetics25529(160)*139.0M7.3 quarters 10-QJun 30, 2026
TG Therapeutics48324039*153.1M— 10-QJun 30, 2026
Catalyst Pharmaceuticals75614960122.4M— 10-QMar 31, 2026
Acadia Pharmaceuticals385308101*172.3M— 10-QJun 30, 2026
Vericel1257716*51.2M— 10-QJun 30, 2026
Recursion Pharmaceuticals55019(77)*622.8M6.2 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.